{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-24-000057","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.540943+00:00","generated_at":"2026-05-30T01:31:57.197157+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon Q3 net loss $64.8M; ZYNQUISTA PDUFA Dec 20 after negative AdCom vote","bullets":["Net loss $64.8M ($0.18/share) vs $50.5M ($0.21) year ago; revenue $1.8M from INPEFA sales.","Licensed sotagliflozin to Viatris for ex-U.S./Europe markets; $25M upfront, up to $197M milestones.","ZYNQUISTA AdCom voted 11-3 that benefits do not outweigh risks; PDUFA target Dec 20, 2024.","INPEFA net sales $1.7M; field force reduced ~50% in September to focus on targeted prescribers.","LX9211 Phase 2b DPNP screening complete, topline data now expected Q1 2025; LX9851 IND on track mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-24-000057","json":"https://secwatch.observer/filing/0001062822-24-000057.json","markdown":"https://secwatch.observer/filing/0001062822-24-000057.md","text":"https://secwatch.observer/filing/0001062822-24-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/0001062822-24-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/lxrx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:31:57.197157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}